Table 4.

Post-diagnostic metformin prescription dispensation and risk of ovarian cancer specific and all-cause mortality in a diabetic ovarian cancer patients.

		Ovarian cancer specific mortality			All-cause mortality
	Person- years	Mortality events (n=412)	Crude HR (95 % CI)	Adjusted HR* (95 % CI)	Mortality events (n=477)	Crude HR (95 % CI)	Adjusted HR* (95 % CI)
Diabetic medication users
Metformin users	1073.66	91	0.65 (0.51-0.84)	0.71 (0.54-0.91)	121	0.74 (0.59-0.92)	0.81 (0.64-1.02)
Non-users	1921.99	321	1	1	356	1	1
Cumulative duration of metformin use, months
<12	294.75	43	0.69 (0.50-0.97)	0.74 (0.53-1.05)	50	0.75 (0.55-1.03)	0.82 (0.59-1.13)
12-24	214.06	24	0.71 (0.46-1.11)	0.74 (0.47-1.16)	33	0.87 (0.59-1.28)	0.89 (0.60-1.33)
24-36	154.90	13	0.67 (0.37-1.21)	0.70 (0.38-1.27)	14	0.60 (0.34-1.06)	0.64 (0.36-1.13)
≥36	409.95	11	0.44 (0.22-0.84)	0.52 (0.27-1.02)	24	0.66 (0.41-1.06)	0.81 (0.50-1.30)
Metformin User type
New use post diagnosis	373.86	21	0.56 (0.35-0.88)	0.64 (0.40-1.02)	34	0.73 (0.51-1.06)	0.88 (0.60-1.28)
Continuing use from pre-diagnosis	699.80	70	0.70 (0.54-0.93)	0.76 (0.56-1.01)	87	0.77 (0.60-0.98)	0.82 (0.63-1.07)
Use only pre-diagnosis	240.68	60	1.25 (0.93-1.70)	1.23 (0.90-1.68)	66	1.33 (0.99-1.77)	1.28 (0.95-1.72)
Never use	1681.31	261	1	1	290	1	1

*Models adjusted for age at diagnosis, diagnosis year, income, surgery after diagnosis, previous cancer, cardiovascular disease, cerebrovascular disease, Peripheral vascular disease, renal disease, Cardiopulmonary disease, hormone replacement therapy, statin, β-blockers, insulin, other diabetic medications